

The GLP-1 Muscle Loss Dilemma

Written by The Life Science Feed Editorial Team · Published 28 May 2026 · Edited by Matt Aldrich

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). **N Engl J Med**. 2021;384(11):989–1002. <https://doi.org/10.1056/NEJMoa2032183>
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). **N Engl J Med**. 2022;387(3):205–216. <https://doi.org/10.1056/NEJMoa2206038>
3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 4 extension). **Diabetes Obes Metab**. 2022;24(8):1553–1564. <https://doi.org/10.1111/dom.14725>
4. Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. **Postgrad Med**. 2018;130(2):173–182. <https://doi.org/10.1080/00325481.2018.1435129>
5. Rubin DA, Hackney AC. Resistance training and GLP-1 receptor agonists: a narrative review of existing literature and implications for preserving lean mass. **J Strength Cond Res**. 2023;37(9):1868–1878. <https://doi.org/10.1519/JSC.0000000000004445>
6. Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. **JAMA Intern Med**. 2021;181(12):1545–1554. <https://doi.org/10.1001/jamainternmed.2021.5607>
7. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. **Lancet**. 2022;399(10322):394–405. [https://doi.org/10.1016/S0140-6736\(21\)01919-X](https://doi.org/10.1016/S0140-6736(21)01919-X)
8. Mechanick JI, Laferrère B, Bays HE, et al. Obesity pillars roundtable: lean mass loss associated with GLP-1 receptor agonist treatment. **Obesity Pillars**. 2023;7:100079. <https://doi.org/10.1016/j.obpill.2023.100079>
9. Lau DCW, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. **CMAJ**. 2007;176(8 Suppl):S1–S13. <https://doi.org/10.1503/cmaj.061409>

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com